European Heart Journal Advance Access originally published online on March 28, 2008
European Heart Journal 2008 29(8):969-983; doi:10.1093/eurheartj/ehn114
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PROactive: time for a critical appraisal
1 Department of Medicine, Royal Free and University College Medical School, University College Hospital, Third Floor, 250 Euston Road, London NW1 2PQ, UK
2 Division of Diabetes, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
3 Division of Cardiology, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA
Received 30 November 2007; revised 18 February 2008; accepted 22 February 2008; online publish-ahead-of-print 28 March 2008.
* Corresponding author. Tel: +44 207 3809336, Fax: +44 207 3809117, Email: j.betteridge{at}ucl.ac.uk
The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) remains the only completed cardiovascular (CV) outcomes study with a thiazolidinedione. It has provided valuable information on the impact of pioglitazone on CV outcomes in a high-risk population of patients with type 2 diabetes and established macrovascular disease. The investigators in PROactive chose a challenging primary composite endpoint that included events in multiple vascular beds (cerebral, cardiac, and peripheral), as well as both disease-related and procedural endpoints. They also pre-specified a more conventional main secondary composite endpoint of all-cause mortality, myocardial infarction, and stroke. Since the results of PROactive were first presented, there has been much debate on the relative merits of the statistically non-significant 10% decrease in the primary endpoint vs. the statistically significant 16% decrease in the main secondary endpoint seen with pioglitazone. However, PROactive includes more information than just these two main endpoints and has provided an extensive safety data set, as well as new insights into the impact of pioglitazone in different patient subpopulations. In this article, we consider all the results from PROactive presented to date and offer our own appraisal of how these findings shape the CV efficacy and safety profile of pioglitazone.
Key Words: Cardiovascular disease • Clinical trial • Pioglitazone • PROactive • Type 2 diabetes
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Hemmingsen, S. S Lund, J. Wetterslev, and A. Vaag Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes Eur. J. Endocrinol., July 1, 2009; 161(1): 1 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Nakaya, B. D. Summers, A. C. Nicholson, A. M. Gotto Jr., D. P. Hajjar, and J. Han Atherosclerosis in LDLR-Knockout Mice Is Inhibited, but Not Reversed, by the PPAR{gamma} Ligand Pioglitazone Am. J. Pathol., June 1, 2009; 174(6): 2007 - 2014. [Abstract] [Full Text] [PDF]
|
|